AbbVie, Inc. (ABBV) is currently at $165.64, down $4.00 or 2.36% --Would be lowest close since July 3, 2024, when it closed at $163.84 --Currently down eight consecutive days; down 17.87% over this ...
Zacks.com on MSN17h
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...
At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...
Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...
Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...
For the three months ended September 30, 2024, Synlogic reported a consolidated net loss of $ (0.1) million, or ($0.01) per share, compared to a consolidated net loss of $ (12.1) million, or $ (2.57) ...
WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported ...
AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...
Dividend growth stocks offer a unique blend of reliability and growth potential, making them an ideal choice for long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback